Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
The Lrrk2 gene modulates the course of infections in mice in a sex-dependent manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
RETRACTED ARTICLE: LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
Bae, E.-J., Kim, D.-K., Kim, C., Mante, M., Adame, A., Rockenstein, E., Ulusoy, A., Klinkenberg, M., Jeong, G. R., Bae, J. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05958-z · Cited by 149
RetractedChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914 · cited 1×
“Whereas the etiology of late-onset, “idiopathic” PD remains to be determined, both genetic and environmental factors are known to contribute (1, 2).”
BackgroundMeta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 1×
“R1441C) mutation and tau dysregulation in others carrying the same mutation (11, 17, 82).”
BackgroundGenome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593
Self-citationCloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112 · cited 1×
“We and others consider the etiology of late-onset PD to be the outcome of interactions among genetic susceptibility (7, 8), encounters with pathogens in the environment and associated tissue responses, with effects due to gender, and the passage of time (9).”
BackgroundShen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. (2016) · eLife · doi:10.7554/elife.12813 · Cited by 1,042 · cited 2×
“Other unanswered questions include whether neighboring genes possibly modulate disease susceptibility, whether a shared function of LRRK2 (19, 21, 52) can explain the association of this gene with three very different disorders, or whether LRRK2 exerts distinct functions in different cell types.”
BackgroundKinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671
NOD proteins: regulators of inflammation in health and disease
Philpott, D. J., Sorbara, M. T., Robertson, S. J., Croitoru, K., & Girardin, S. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3565 · Cited by 668
Self-citation(2007) · YUHSpace (Yonsei University Medical Library) · doi:10.1016/s1474 · Cited by 641
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2006) · Nature Neuroscience · doi:10.1038/nn1776 · Cited by 619
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570
The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology
MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., & Abeliovich, A. (2006) · Neuron · doi:10.1016/j.neuron.2006.10.008 · Cited by 564
LRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. R. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2935 · Cited by 539
Invited Article: Nervous system pathology in sporadic Parkinson disease
Braak, H., & Del Tredici, K. (2008) · Neurology · doi:10.1212/01.wnl.0000312279.49272.9f · Cited by 538
Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., & Shen, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004676107 · Cited by 501
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463 · cited 10×
“A possible concomitant role for murine Lrrk2 in microgliamediated responses could contribute to the results described in our work, as several laboratories have recently demonstrated such an effect in different animal models (57, 70, 95).”
BackgroundResultInfluentialRobinson, N., McComb, S., Mulligan, R., Dudani, R., Krishnan, L., & Sad, S. (2012) · Nature Immunology · doi:10.1038/ni.2397 · Cited by 438
Self-citationYarilina, A., Park-Min, K.-H., Antoniv, T., Hu, X., & Ivashkiv, L. B. (2008) · Nature Immunology · doi:10.1038/ni1576 · Cited by 429
LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens
Gardet, A., Benita, Y., Li, C., Sands, B. E., Ballester, I., Stevens, C., Korzenik, J. R., Rioux, J. D., Daly, M. J., Xavier, R. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000548 · Cited by 415
Self-citationRamonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018568 · Cited by 405
Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease
Kalia, L. V., Lang, A. E., Hazrati, L.-N., Fujioka, S., Wszolek, Z. K., Dickson, D. W., Ross, O. A., Van Deerlin, V. M., Trojanowski, J. Q., Hurtig, H. I., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2704 · Cited by 384 · cited 2×
“R1441C) mutation and tau dysregulation in others carrying the same mutation (11, 17, 82).”
BackgroundHui, K. Y., Fernandez-Hernandez, H., Hu, J., Schaffner, A., Pankratz, N., Hsu, N.-Y., Chuang, L.-S., Carmi, S., Villaverde, N., Li, X., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7795 · Cited by 384
Self-citationLiu, Z., Lee, J., Krummey, S., Lu, W., Cai, H., & Lenardo, M. J. (2011) · Nature Immunology · doi:10.1038/ni.2113 · Cited by 361
Herzig, M. C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T. J., Schmid, P., Danner, S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr348 · Cited by 360 · cited 2×
“G2019S mutant Lrrk2-expressing mice and wild-type mice (56).”
BackgroundSelf-citationEffect of selective LRRK2 kinase inhibition on nonhuman primate lung
Fuji, R. N., Flagella, M., Baca, M., S. Baptista, M. A., Brodbeck, J., Chan, B. K., Fiske, B. K., Honigberg, L., Jubb, A. M., Katavolos, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3634 · Cited by 352
Ross, O. A., Soto-Ortolaza, A. I., Heckman, M. G., Aasly, J. O., Abahuni, N., Annesi, G., Bacon, J. A., Bardien, S., Bozi, M., Brice, A., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70175-2 · Cited by 336
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
Lee, B. D., Shin, J.-H., VanKampen, J., Petrucelli, L., West, A. B., Ko, H. S., Lee, Y.-I., Maguire-Zeiss, K. A., Bowers, W. J., Federoff, H. J., et al. (2010) · Nature Medicine · doi:10.1038/nm.2199 · Cited by 329
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice
Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E. N., & Shen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906334106 · Cited by 304 · cited 1×
“R1441C Lrrk2 mutation that alters Lrrk2 guanosine triphosphatase (GTPase) activity (37, 76), in a smaller study.”
BackgroundCullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303
Self-citationHakimi, M., Selvanantham, T., Swinton, E., Padmore, R. F., Tong, Y., Kabbach, G., Venderova, K., Girardin, S. E., Bulman, D. E., Scherzer, C. R., et al. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0653-2 · Cited by 283
Self-citationProgressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice
Yue, M., Hinkle, K. M., Davies, P., Trushina, E., Fiesel, F. C., Christenson, T. A., Schroeder, A. S., Zhang, L., Bowles, E., Behrouz, B., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.031 · Cited by 281
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo
Cullen, V., Lindfors, M., Ng, J., Paetau, A., Swinton, E., Kolodziej, P., Boston, H., Saftig, P., Woulfe, J., Feany, M. B., et al. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-5 · Cited by 279
Self-citationLRRK2 levels in immune cells are increased in Parkinson’s disease
Cook, D. A., Kannarkat, G. T., Cintron, A. F., Butkovich, L. M., Fraser, K. B., Chang, J., Grigoryan, N., Factor, S. A., West, A. B., Boss, J. M., et al. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0010-8 · Cited by 279 · cited 1×
“LRRK2 expression has also been detected in isolated human neutrophils (60, 63).”
BackgroundThe vermiform appendix impacts the risk of developing Parkinson’s disease
Killinger, B. A., Madaj, Z., Sikora, J. W., Rey, N., Haas, A. J., Vepa, Y., Lindqvist, D., Chen, H., Thomas, P. M., Brundin, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5280 · Cited by 279
Genetic Factors Are Not the Major Causes of Chronic Diseases
Rappaport, S. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154387 · Cited by 248 · cited 1×
“This concept of “complex disease” development, whereby multiple factors are essential to generate a disease phenotype, is similar to other late-onset diseases in humans (10).”
ResultAbrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats
Daher, J. P. L., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S., & West, A. B. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403215111 · Cited by 223
Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N., Chou, M.-Y., Howden, A. J. M., König, T., Hotzy, C., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20180248 · Cited by 222
Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain
Beatman, E. L., Massey, A., Shives, K. D., Burrack, K. S., Chamanian, M., Morrison, T. E., & Beckham, J. D. (2016) · Journal of Virology · doi:10.1128/jvi.02949-15 · Cited by 214
Berger, Z., Smith, K. A., & LaVoie, M. J. (2010) · Biochemistry · doi:10.1021/bi100157u · Cited by 213 · cited 1×
“1, C and D) using a well characterized antibody to LRRK2 (55, 73).”
MethodDaher, J. P. L., Abdelmotilib, H. A., Hu, X., Volpicelli-Daley, L. A., Moehle, M. S., Fraser, K. B., Needle, E., Chen, Y., Steyn, S. J., Galatsis, P., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.660001 · Cited by 210
Commensal bacteria direct selective cargo sorting to promote symbiosis
Zhang, Q., Pan, Y., Yan, R., Zeng, B., Wang, H., Zhang, X., Li, W., Wei, H., & Liu, Z. (2015) · Nature Immunology · doi:10.1038/ni.3233 · Cited by 206 · cited 3×
“G2019S mutant Lrrk2, it is plausible that the pro-inflammatory response is evolutionarily advantageous to a host that has been invaded by potentially lethal bacteria (64, 89).”
BackgroundA Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy
Fava, V. M., Manry, J., Cobat, A., Orlova, M., Van Thuc, N., Ba, N. N., Thai, V. H., Abel, L., Alcaïs, A., Schurr, E., et al. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004412 · Cited by 204
Regulation of LRRK2 Expression Points to a Functional Role in Human Monocyte Maturation
Thévenet, J., Pescini Gobert, R., Hooft van Huijsduijnen, R., Wiessner, C., & Sagot, Y. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021519 · Cited by 189
G2019S-LRRK2 Expression Augments -Synuclein Sequestration into Inclusions in Neurons
Volpicelli-Daley, L. A., Abdelmotilib, H., Liu, Z., Stoyka, L., Daher, J. P. L., Milnerwood, A. J., Unni, V. K., Hirst, W. D., Yue, Z., Zhao, H. T., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3642-15.2016 · Cited by 185
Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain
Higashi, S., Biskup, S., West, A. B., Trinkaus, D. B., Dawson, V. L., Faull, R. L. M., Waldvogel, H. J., Arai, H., Dawson, T. M., Moore, D. J., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.04.034 · Cited by 182
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
West, A. B. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.019 · Cited by 176
Baptista, M. A. S., Dave, K. D., Frasier, M. A., Sherer, T. B., Greeley, M., Beck, M. J., Varsho, J. S., Parker, G. A., Moore, C., Churchill, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080705 · Cited by 175
LRRK2 expression linked to dopamine‐innervated areas
Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O., & Olson, L. (2006) · Annals of Neurology · doi:10.1002/ana.20808 · Cited by 174 · cited 1×
“An important question that remains is the identity of the most responsible cell type that promotes pathogenesis in LRRK2-linked parkinsonism (42, 43).”
BackgroundLRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages
Härtlova, A., Herbst, S., Peltier, J., Rodgers, A., Bilkei‐Gorzo, O., Fearns, A., Dill, B. D., Lee, H., Flynn, R., Cowley, S. A., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798694 · Cited by 174
Fan, Y., Howden, A. J. M., Sarhan, A. R., Lis, P., Ito, G., Martinez, T. N., Brockmann, K., Gasser, T., Alessi, D. R., & Sammler, E. M. (2018) · Biochemical Journal · doi:10.1042/bcj20170803 · Cited by 173
Lee, G., & Leugers, C. J. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00004-7 · Cited by 165
LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection
Liu, W., Liu, X., Li, Y., Zhao, J., Liu, Z., Hu, Z., Wang, Y., Yao, Y., Miller, A. W., Su, B., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170014 · Cited by 165 · cited 2×
“The second report used a Salmonella infection model similar to ours to highlight the role of Lrrk2-mediated Nlrc4 inflammasome activation in the control of infection in mice (75).”
MethodResultAge-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium
Marder, K., Wang, Y., Alcalay, R. N., Mejia-Santana, H., Tang, M.-X., Lee, A., Raymond, D., Mirelman, A., Saunders-Pullman, R., Clark, L., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001708 · Cited by 161
LRRK2 mutations in Parkinson disease
Farrer, M., Stone, J., Mata, I. F., Lincoln, S., Kachergus, J., Hulihan, M., Strain, K. J., & Maraganore, D. M. (2005) · Neurology · doi:10.1212/01.wnl.0000169023.51764.b0 · Cited by 152
LRRK2 Pathways Leading to Neurodegeneration
Cookson, M. R. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0564-y · Cited by 139
Schapansky, J., Khasnavis, S., DeAndrade, M. P., Nardozzi, J. D., Falkson, S. R., Boyd, J. D., Sanderson, J. B., Bartels, T., Melrose, H. L., & LaVoie, M. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.12.005 · Cited by 136
West, A. B., Cowell, R. M., Daher, J. P. L., Moehle, M. S., Hinkle, K. M., Melrose, H. L., Standaert, D. G., & Volpicelli‐Daley, L. A. (2014) · Journal of Comparative Neurology · doi:10.1002/cne.23583 · Cited by 134
LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity
Heo, H. Y., Park, J.-M., Kim, C.-H., Han, B., Kim, K., & Seol, W. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.09.014 · Cited by 133 · cited 1×
“These results were consistent with a previous report that Lrrk2 mediated reactive oxygen species production in mouse dopaminergic neurons of the substantia nigra (78).”
ResultThe complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease
Schapansky, J., Nardozzi, J. D., & LaVoie, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.049 · Cited by 132 · cited 3×
“These effects were attributed to reduced inflammation (58, 70, 71).”
BackgroundAlpha‐synuclein in the appendiceal mucosa of neurologically intact subjects
Gray, M. T., Munoz, D. G., Gray, D. A., Schlossmacher, M. G., & Woulfe, J. M. (2014) · Movement Disorders · doi:10.1002/mds.25779 · Cited by 132
Self-citationGiaime, E., Tong, Y., Wagner, L. K., Yuan, Y., Huang, G., & Shen, J. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.036 · Cited by 131 · cited 1×
“Nevertheless, it remains unknown how these LRRK2 mutations lead to neurodegeneration (26).”
BackgroundWebber, P. J., Smith, A. D., Sen, S., Renfrow, M. B., Mobley, J. A., & West, A. B. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.07.033 · Cited by 125 · cited 1×
“R1441C Lrrk2 mutation that alters Lrrk2 guanosine triphosphatase (GTPase) activity (37, 76), in a smaller study.”
BackgroundDisease Penetrance of Late-Onset Parkinsonism: A Meta-analysis
Trinh, J., Guella, I., & Farrer, M. J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1909 · Cited by 125
Kim, K. S., Marcogliese, P. C., Yang, J., Callaghan, S. M., Resende, V., Abdel-Messih, E., Marras, C., Visanji, N. P., Huang, J., Schlossmacher, M. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718946115 · Cited by 111
Self-citationDysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration
Jeong, G. R., Jang, E.-H., Bae, J. R., Jun, S., Kang, H. C., Park, C.-H., Shin, J.-H., Yamamoto, Y., Tanaka-Yamamoto, K., Dawson, V. L., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0240-1 · Cited by 104
Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers
Dzamko, N., Rowe, D. B., & Halliday, G. M. (2016) · Movement Disorders · doi:10.1002/mds.26529 · Cited by 98 · cited 1×
“G2019S LRRK2 carriers were shown to have altered inflammatory markers in their biological fluids (72).”
BackgroundTsika, E., Kannan, M., Foo, C. S.-Y., Dikeman, D. A., Glauser, L., Gellhaar, S., Galter, D., Knott, G. W., Dawson, T. M., Dawson, V. L., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.027 · Cited by 93
The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases
Singleton, A., & Hardy, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.040 · Cited by 91
Ness, D., Ren, Z., Gardai, S., Sharpnack, D., Johnson, V. J., Brennan, R. J., Brigham, E. F., & Olaharski, A. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066164 · Cited by 88
Trinh, J., Gustavsson, E. K., Vilariño‐Güell, C., Bortnick, S., Latourelle, J. C., McKenzie, M. B., Szu‐Tu, C., Nosova, E., Khinda, J., Milnerwood, A. J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30203-4 · Cited by 85
A Common Genetic Fingerprint in Leprosy and Crohn's Disease?
Schurr, E., & Gros, P. (2009) · New England Journal of Medicine · doi:10.1056/nejme0910690 · Cited by 78
A comparative study of Lrrk2 function in primary neuronal cultures
Dächsel, J. C., Behrouz, B., Yue, M., Beevers, J. E., Melrose, H. L., & Farrer, M. J. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.08.018 · Cited by 77
Shutinoski, B., Alturki, N. A., Rijal, D., Bertin, J., Gough, P. J., Schlossmacher, M. G., & Sad, S. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.51 · Cited by 75 · cited 1×
“We chose a sepsis model induced by the intravenous inoculation of adult mice with Salmonella typhimurium, a facultative anaerobe and Gramnegative bacterium (74).”
MethodSelf-citationMoehle, M. S., Daher, J. P. L., Hull, T. D., Boddu, R., Abdelmotilib, H. A., Mobley, J., Kannarkat, G. T., Tansey, M. G., & West, A. B. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv157 · Cited by 74
Kuss, M., Adamopoulou, E., & Kahle, P. J. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12668 · Cited by 72
LRRK2 but not ATG16L1 is associated with Paneth cell defect in Japanese Crohn’s disease patients
Liu, T.-C., Naito, T., Liu, Z., VanDussen, K. L., Haritunians, T., Li, D., Endo, K., Kawai, Y., Nagasaki, M., Kinouchi, Y., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91917 · Cited by 68
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice
Novello, S., Arcuri, L., Dovero, S., Dutheil, N., Shimshek, D. R., Bezard, E., & Morari, M. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.018 · Cited by 68
Self-citationTomlinson, J. J., Shutinoski, B., Dong, L., Meng, F., Elleithy, D., Lengacher, N. A., Nguyen, A. P., Cron, G. O., Jiang, Q., Roberson, E. D., et al. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1726-7 · Cited by 63
Self-citationRudenko, I. N., & Cookson, M. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0284-z · Cited by 61
LRRK2 mutations in Parkinson's disease: Confirmation of a gender effect in the Italian population
Cilia, R., Siri, C., Rusconi, D., Allegra, R., Ghiglietti, A., Sacilotto, G., Zini, M., Zecchinelli, A. L., Asselta, R., Duga, S., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.04.016 · Cited by 55
Ma, Y., Chen, H., Wang, Q., Luo, F., Yan, J., & Zhang, X. (2009) · European Journal of Immunology · doi:10.1002/eji.200939678 · Cited by 50
LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis
Gan‐Or, Z., Leblond, C. S., Mallett, V. M., Orr‐Urtreger, A., Dion, P. A., & Rouleau, G. A. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.002 · Cited by 48
The Salmonella effector protein SifA plays a dual role in virulence
Zhao, W., Moest, T., Zhao, Y., Guilhon, A., Buffat, C., Gorvel, J., & Méresse, S. (2015) · Scientific Reports · doi:10.1038/srep12979 · Cited by 48
Salazar, G. A., Peñaloza, H. F., Pardo‐Roa, C., Schultz, B. M., Muñoz‐Durango, N., Gómez, R. S., Salazar, F. J., Pizarro, D. P., Riedel, C. A., González, P. A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00889 · Cited by 48
Tsika, E., Nguyen, A. P. T., Dusonchet, J., Colin, P., Schneider, B. L., & Moore, D. J. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.019 · Cited by 46
Self-citationLeucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury
Boddu, R., Hull, T. D., Bolisetty, S., Hu, X., Moehle, M. S., Daher, J. P. L., Kamal, A. I., Joseph, R., George, J. F., Agarwal, A., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv147 · Cited by 43
Xiong, Y., Neifert, S., Karuppagounder, S. S., Stankowski, J. N., Lee, B. D., Grima, J. C., Chen, G., Ko, H. S., Lee, Y., Swing, D., et al. (2017) · eneuro · doi:10.1523/eneuro.0004-17.2017 · Cited by 41
Walker, M. D., Volta, M., Cataldi, S., Dinelle, K., Beccano-Kelly, D. A., Munsie, L. N., Kornelsen, R. A., Mah, C. J., Chou, P., Co, K., et al. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140344 · Cited by 38
Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease
Luciano, M. S., Wang, C., Ortega, R. A., Giladi, N., Marder, K. S., Bressman, S., & Saunders-Pullman, R. J. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.489 · Cited by 36
Nucleotide sequence comparison of the M1 genome segment of reovirus type 1 Lang and type 3 Dearing
Zou, S., & Brown, E. G. (1992) · Virus Research · doi:10.1016/0168-1702(92)90042-8 · Cited by 32
Self-citationSchlossmacher, M. G., Tomlinson, J. J., dos Santos, G. M., Shutinoski, B., Brown, E. G., Manuel, D. G., & Mestre, T. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13476 · Cited by 32
Self-citationLRRK2 and Nod2 promote lysozyme sorting in Paneth cells
da Rocha, J. D. B., Schlossmacher, M. G., & Philpott, D. J. (2015) · Nature Immunology · doi:10.1038/ni.3255 · Cited by 31 · cited 1×
“G2019S mutant Lrrk2, it is plausible that the pro-inflammatory response is evolutionarily advantageous to a host that has been invaded by potentially lethal bacteria (64, 89).”
BackgroundSelf-citationType I Interferons Inhibit Maturation and Activation of Mouse Langerhans Cells
Fujita, H., Asahina, A., Tada, Y., Fujiwara, H., & Tamaki, K. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23803.x · Cited by 28 · cited 2×
“These include IL-10 deficiency, IL-35 deletion in B cells, ablation of IFN-1 signaling, and Skip deficiency (90–93).”
BackgroundGauvin, L. G., Bennett, S. A. L., Liu, H., Hakimi, M., Schlossmacher, M. G., Majithia, J., & Brown, E. G. (2013) · Virology Journal · doi:10.1186/1743-422x-10-67 · Cited by 27 · cited 5×
“7 × 105 PFU, which we defined as one LD50 in a previous study (79).”
BackgroundMethodInfluentialSelf-citationLitteljohn, D., Rudyk, C., Dwyer, Z., Farmer, K., Fortin, T., & Hayley, S. P. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.09.002 · Cited by 27
Self-citationWu, A. G., Pruijssers, A. J. P., Brown, J. J., Stencel-Baerenwald, J., Sutherland, D. M., Iskarpatyoti, J. A., & Dermody, T. S. (2018) · Pediatric Research · doi:10.1038/pr.2018.13 · Cited by 24 · cited 1×
“Whether this protective effect by genetically engineered kinase ablation was caused by a lesser immune response by infiltrating leukocytes or altered responses to pathogens by resident neurons and glia remains to be determined (96).”
BackgroundIdentical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease
Xiromerisiou, G., Houlden, H., Sailer, A., Silveira‐Moriyama, L., Hardy, J., & Lees, A. J. (2012) · Movement Disorders · doi:10.1002/mds.24924 · Cited by 20 · cited 1×
“Given the relatively low mean penetrance rate for carriers of an LRRK2 mutation across multiple ethnicities, it is plausible that either a genetic or environmental cofactor may be required to express the PD phenotype (27, 28).”
Background
Cited by
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis
Weindel, C. G., Martinez, E. L., Zhao, X., Mabry, C. J., Bell, S. L., Vail, K. J., Coleman, A. K., VanPortfliet, J. J., Zhao, B., Wagner, A. R., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.038 · Cited by 396
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 366
“Moreover, LRRK2 has been detected in B lymphocytes and macrophages, indicating an active participation in immune response [76].”
BackgroundLRRK 2 activation controls the repair of damaged endomembranes in macrophages
Herbst, S., Campbell, P., Harvey, J., Bernard, E. M., Papayannopoulos, V., Wood, N. W., Morris, H. R., & Gutierrez, M. G. (2020) · The EMBO Journal · doi:10.15252/embj.2020104494 · Cited by 194
“Our findings are consistent with previous reports showing that the effect of LRRK2 on pathogen immunity depends on the pathogen (Shutinoski et al , 2019).”
Metadata
- Authors
- Shutinoski, B., Hakimi, M., Harmsen, I. E., Lunn, M., Rocha, J., Lengacher, N., Zhou, Y. Y., Khan, J., Nguyen, A., Hake-Volling, Q., El-Kodsi, D., Li, J., Alikashani, A., Beauchamp, C., Majithia, J., Coombs, K., Shimshek, D., Marcogliese, P. C., Park, D. S., Rioux, J. D., Philpott, D. J., Woulfe, J. M., Hayley, S., Sad, S., Tomlinson, J. J., Brown, E. G., & Schlossmacher, M. G.
- Affiliations
- University of Ottawa (CA)
- University of Toronto (CA)
- Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
- Montreal Heart Institute (CA)
- University of Manitoba (CA)
- Novartis (Switzerland) (CH)
- Carleton University (CA)
- Corresponding author
- Shutinoski, Bojan
- Hakimi, Mansoureh
- Schlossmacher, Michael G.
- ORCID
- Shutinoski, Bojan
- Hakimi, Mansoureh
- Harmsen, Irene E.
- Lunn, Michaela
- Rocha, Juliana
- Lengacher, Nathalie
- Zhou, Yi Yuan
- Khan, Jasmine
- Nguyen, Angela
- Hake-Volling, Quinton
- El-Kodsi, Daniel
- Li, Juan
- Alikashani, Azadeh
- Coombs, Kevin
- Shimshek, Derya
- Marcogliese, Paul C.
- Park, David S.
- Rioux, John D.
- Philpott, Dana J.
- Woulfe, John M.
- Hayley, Shawn
- Sad, Subash
- Tomlinson, Julianna J.
- Brown, Earl G.
- Schlossmacher, Michael G.
- Venue
- Science Translational Medicine
- Published
- 2019-09-25
- Volume
- 11
- Issue
- 511
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2975050401
- Cited by
- 96
- References
- 102
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 14 · 2023: 15 · 2022: 16 · 2021: 8 · 2020: 19 · 2019: 1
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- The Novartis Repository (Novartis) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- LRRK2, inflammation, microbial infection, sex differences, host genetics, mouse model
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Alleles, Animals, Brain, Chemotaxis, Encephalitis, Female, Humans, Infections, Inflammation, Leukocytes, Male, Mice, Inbred C57BL, Mutation, Reoviridae, Salmonella typhimurium, Sex Characteristics, Survival Analysis, Reactive Oxygen Species, Sepsis, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.